Skip to content

Our lead product for severe pneumonia, plasma gelsolin, has application for COVID19.

HOME
ABOUT US
OUR SCIENCE
OUR PLATFORM
NEWS
PUBLICATIONS
CONTACT

Menu

HOME
ABOUT US
OUR SCIENCE
OUR PLATFORM
NEWS
PUBLICATIONS
CONTACT

News

Exciting news about plasma gelsolin therapy and BioAegis Therapeutics discoveries on infectious, inflammatory and degenerative diseases.

November, 2017: Community Acquired Pneumonia Etiology Review in Clinical Infectious Diseases Reinforces Need for Host-Based Approach

November 15, 2017

October, 2017: BioAegis Therapeutics and the T.H. Chan-Harvard School of Public Health Demonstrate “Delayed Therapy with Plasma Gelsolin Improves Survival in Murine Pneumococcal Pneumonia” at ID Week

October 20, 2017

October, 2017: BioAegis Therapeutics Hires Dr. Mark J. DiNubile as Chief Medical Officer to Spearhead Forthcoming Phase 2 Clinical Trials in Community-Acquired Pneumonia

October 20, 2017

September, 2017: Dr. Thomas P. Stossel, BioAegis Therapeutics’ Founding Scientist Presents The 24th Annual William C. Moloney Lecture

September 30, 2017

June, 2017: BioAegis to Present at Marcum 2017 Microcap Conference

June 10, 2017

May, 2017: BioAegis Chosen to Present at the Cavendish Washington, DC Health Impact Forum

May 1, 2017

April, 2017: BioAegis Therapeutics Presents to Investors at the MACRO Trends Conference in Antwerp, Belgium

April 25, 2017

February, 2017: BioAegis Therapeutics Announces Addition of Leading Critical Care Nephrologist to its Clinical Advisory Board

February 27, 2017

Page1 Page2 Page3 Page4 Page5 … Page8

Stay informed of our latest discoveries and news.

EMAIL

GENERAL NEWS

April, 2020: Small NJ Biotech Firm, BioAegis Therapeutics, Accelerating Multiple Clinical Trial Submissions for Severe COVID-19 Pneumonia Patients

April 2, 2020

March 2020: Chief Medical Officer Discusses COVID-19 in KYW InDepth Podcast

March 27, 2020

February, 2020: BioAegis Commentary Featured on CNBC

February 25, 2020

SCIENTIFIC PUBLICATIONS

Low Admission Plasma Gelsolin Concentrations Identify Community-acquired Pneumonia Patients at High Risk for Severe Outcomes.

Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.

Delayed administration of recombinant plasma gelsolin improves survival in a murine model of severe influenza.

COMPANY DETAILS

LOCATION:
BioAegis Therapeutics
North Brunswick, NJ

MEDIA INQUIRIES:
Contact: Christine Lagana
clagana@bioaegistx.com

INVESTOR INQUIRIES:
Contact: Steven Cordovano
scordovano@bioaegistx.com

JOIN OUR TEAM

FOLLOW US

Facebook Twitter Linkedin Youtube

© 2020 BioAegis Therapeutics Inc. | Privacy Policy | Terms of Use